The updated guidance, which was largely driven by lower-than-anticipated sales of GLP-1 blockbusters Mounjaro and Zepbound, ...

This is just a glimpse of the insights available to CivicScience clients. Want to see the full picture? Let’s talk. As the ...

Unfortunately for the company, however, the early glimpse at its fourth-quarter performance doesn’t seem to be going over ...

Sana Biotechnology said a type 1 diabetes (T1D) patient received an allogeneic primary islet cell transplantation without ...

Data from Hengrui’s Phase II trial for its GLP-1/GIP product demonstrated a statistically significant mean weight loss of ...

For the first time in over a decade, obesity rates have dropped in the United States. A recent study by the CDC showed that ...

The Dow, S&P 500, and Nasdaq are gaining Tuesday as the stock market digests a report on producer price inflation and rising bond yields.

Lilly revised its revenue guidance down 5%, to $13.5 billion, missing consensus of $14 billion by $500 million. But the guidance still represents a 45% increase from the same quarter in 2023. Lilly ...

Ozempic, approved for Type 2 diabetes, has gained fame for its weight-loss properties, especially among celebrities. Despite its rising popularity, ex ...

The company also dropped a clue about who is -- or isn't -- winning market share in GLP-1 drug sales. In a press release this ...

Can weight loss drugs curb alcohol addictions? This Louisiana doctor is keeping an eye on new findings and emerging research.

Research reveals groundbreaking results about Mounjaro and Ozempic in weight loss treatment. Here's what you need to know ...